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Abstract
Menopause may affect antiretroviral treatment (ART) response. Immunologic and virologic
responses to ART were compared in 220 pre- and 47 post-menopausal women enrolled in two ART-
naive studies. Changes in CD4 counts or HIV-1 RNA were similar at 24, 48, or 96 weeks. Treatment-
naïve women should respond to ART regardless of menopausal status.
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Introduction
Half of the individuals living with HIV/AIDS worldwide are women [1]. In 2006, 15% of
newly diagnosed cases of HIV in the United States were in individuals above the age of 50
[2]. The number of mature women who will become HIV-infected or who will live with HIV
is expected to increase as overall life expectancy increases. HIV-infected women will have
already undergone or will undergo the menopause transition during the course of their disease.
The differences between how HIV-infected and HIV-uninfected women experience
menopause are only recently under investigation [3]. Despite these efforts, there is a paucity
of information regarding initial treatment responses to antiretroviral therapy (ART) in post-
menopausal women.
Younger HIV-infected women have higher CD4 counts and lower HIV-1 RNA, on average,
when compared to age-matched HIV-infected men in early disease and prior to receiving ART
[4-7]. These differences may be explained by estrogen’s effect on immune function and HIV
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replication [8]. Menopause is the natural aging process resulting in decreased ovarian synthesis
of estrogen. Post-menopausal woman may therefore have different baseline CD4 counts and
HIV-1 RNA as well as different ART treatment responses as compared to pre-menopausal
women. The goal of this study is to compare long-term immunologic and virologic responses
to initial ART in pre- and post-menopausal women participating in two treatment trials.
Methods
Women who enrolled into two recently completed multi-center treatment-naïve studies
coordinated by the AIDS Clinical Trials Group (ACTG 5095 and ACTG 5142)[9,10]Women
were included if gynecological data within the first 24 weeks of ART were obtained.
Menopause was defined as a cessation of menses ≥ 6 months plus documented follicle
stimulating hormone > 35 miu/mL at any age. Women ≤ 30 years and without bilateral
oophorectomy at ART initiation were classified as pre-menopausal. Women ≥ 55 years were
categorized as post-menopausal. Women with bilateral oophorectomy were classified as
postmenopausal, regardless of age. Menopause status of women > 31 to < 54 years was
determined by self-report and standard questionnaire. CD4 counts and HIV-1 RNA were
collected at pre-determined intervals according to the parent protocol. All CD4 counts were
processed at local CLIA certified labs and HIV-1 RNA (ultrasensitive Amplicor HIV-1 RNA
Assay, Roche Diagnostic Systems) were processed at one central laboratory.
Immunologic and virologic responses after 24, 48 and 96 weeks of ART irrespective of type
or changes in ART were analyzed. All women received one of four randomized treatment
categories according to the original protocols: NRTI only, NRTI plus NNRTI, PI plus NRTI,
or PI plus NNRTI.
Quantitative variables were compared between pre- and post-menopausal women using the
Kruskal-Wallis Test, and categorical variables were compared using Fisher’s Exact Test.
Logistic regression was used to compare the odds of virologic suppression adjusting for pre-
treatment log10 HIV-1 RNA.
Results
Characteristics of Study Population
Among 367 women who entered into the two treatment-naïve protocols, 319 (87%) had
gynecological data obtained within 24 weeks of ART initiation. Most of the women who did
not have data were enrolled prior to the parent protocol amendment that introduced this data
collection. Sixty-three women < 31 years and 23 women ≥ 55 years at the time of ART initiation
were characterized as pre- and post-menopausal, respectively. Of the 233 women ≥31 and <55
years, 157 were categorized as pre-menopausal and 24 as post-menopausal. The remaining 52
women were excluded for reporting peri-menopausal symptoms (N=13), unknown menopausal
status (N=12), or changed menopausal status during follow-up (N=27). In summary, 267
women were included in the final analysis: 220 pre-menopausal and 47 post-menopausal
women.
Age was significantly lower for pre- versus post-menopausal women (median 35 vs. 54 years;
p < 0.001) Pre-menopausal women were less likely than post-menopausal women to have
undergone a hysterectomy (2% vs. 55%; p<0.001) (Table 1). Race/ethnicity, injection drug
use or initial treatment regimens did not differ between the two groups. Median pre-treatment
CD4 count was 181 and 244 cells/ul (p=0.22) in pre- and post-menopausal women,
respectively. Pre-menopausal women had significantly lower median pre-treatment HIV-1
RNA level (45,938 vs. 96,021 copies/ml corresponding to a difference of 0.32 log10 copies/
ml; p= 0.006).
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Of the 267 women, 259 (97%), 251 (94%) and 220 (82%) were followed to 24, 48 and 96
weeks, respectively, with similar follow up between pre- and post-menopausal women.
Nineteen percent (n= 41) of the pre- and 13% (n=6) of the post-menopausal women were
without 96 weeks follow-up (p=0.40). Fifteen completed protocol follow-up before week 96
(12 pre vs 3 postmenopausal, respectively), 10 were no longer able to get to the clinic for follow
up (8 vs 2), 9 were not able to comply with protocol requirements (9 vs 0), 7 were no longer
able to be contacted (7 vs 0), 3 had severe debilitation and were unable to continue (2 vs 1),
and 3 pre-menopausal women for miscellaneous reasons (1 deceased, 1 withdrew consent and
1 for unspecified reason).
The median change in CD4 count did not differ between pre- and post-menopausal women at
24 weeks (118 vs. 116; p=0.99), 48 weeks (185 vs. 195; p= 0.42) or 96 weeks (260 vs. 273
cells/ul; p= 0.51); nor were there significant differences in median change in CD4 % at 24 (7.0
vs 7.0; p=0.77), 48 (9.0 vs 9.0; p=0.74) or 96 weeks (11.0 vs 12.0%; p=0.79).
Although pre-menopausal women had lower median pre-treatment HIV-1 RNA, there were no
differences between groups in the proportion of women with measurements who achieved an
HIV-1 RNA ≤50 copies/ml at 24 (74% vs. 68%; p=0.46), 48 (77% vs. 81%; p=0.69) or 96
weeks (75% vs. 77%; p>0.99). There were no differences in the odds of achieving an HIV-1
RNA ≤50 copies/mL for pre-menopausal compared with post-menopausal women after
adjusting for pre-treatment HIV-1 RNA at 24 (OR 1.17; 95% CI: 0.57, 2.41), 48 (OR 0.78;
95% CI: 0.33, 1.82) or 96 weeks (OR 0.82; 95% CI: 0.36, 1.89).
Discussion
The increase in HIV incidence in individuals above the age of 50 [2,11] is likely due to greater
acceptability of testing; refinement of surveillance testing; incorporation of testing into daily
medical care; and increases in AIDS-defining illnesses in previously undiagnosed individuals
[12]. The prevalence is also increasing due to more widespread use of ART. Post-menopausal
women may be especially vulnerable to HIV acquisition due to the physiological changes in
the vaginal mucosa associated with diminished estrogen. Post-menopausal women may not
perceive themselves to be at risk and therefore may not practice safe sex [13]. Compounded,
these factors will likely result in an increase in new HIV/AIDS diagnoses in postmenopausal
women, which in turn, will increase the number of ART-naïve postmenopausal women
requiring treatment.
With the growing population of HIV-infected women, understanding differences in
immunologic and virologic responses to ART across the naturally occurring physiological
changes is important. This analysis demonstrates the similarity in virologic and immunologic
responses to ART in treatment naïve pre- and post-menopausal women initiating ART in a
clinical trial setting. Among women followed for 96 weeks after initiating ART, there were no
differences in the median change in CD4 count or CD4% between these pre- and
postmenopausal women. Nor were there differences in the proportion of women who achieved
HIV-1 RNA ≤ 50 copies/ml at 24, 48 or 96 weeks. Differentiating age and adherence effects
is difficult and can only be performed with larger numbers of participants. Nonetheless, this
study supports a smaller clinical cohort study [14] that women respond equally well to ART
in the short and long term regardless of menopause status.
There were some notable differences between the two groups in pre-treatment levels worth
noting. Post-menopausal women had higher median HIV-1 RNA at baseline. This difference
was small (0.32 log10 copies/ml) but was significant and is also similar to that seen between
men and predominantly pre-menopausal women [12]. An analysis between age-matched men
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and women is a planned within the ACTG. Nonetheless, the percentages of post-menopausal
women achieving HIV-1 RNA ≤ 50 copies/mL at pre-specified time points did not differ from
those of pre-menopausal women. This observation is consistent with other clinical trial
outcomes suggesting that baseline HIV-1 RNA is not a strong predictor of long-term virologic
responses [15] [16]. Because time since seroconversion is unknown, we cannot rule out the
possibility that our findings might be affected by other factors such as healthy survivor effects
or by frailty selection bias.
This analysis used clinical trial data in which care was standardized and therefore avoids some
of the problems seen in cohort studies. The similarity in CD4 counts and viral load after
initiating ART suggest that all women should be treated similarly regardless of age. While the
number of post-menopausal women was small in this analysis, the confidence intervals for the
odds ratio comparing groups in the proportion of women achieving HIV-1 RNA ≤50 copies/
ml allow us to rule out substantial differences in long term suppression rates. This report did
not, however, include measurements of antiretroviral-related toxicity or other adverse events
which have been reported to be increased among older individuals [17-19]. Despite this
theoretical concern, 77% of the post-menopausal women (and 75% of premenopausal women)
with HIV-1 RNA measurements were virologically suppressed at 96 weeks. Future analysis
should address differences in toxicities that may impair adherence and sustainable responses.
We present data on the largest number of ART naïve women with well-characterized
menopause status who received standardized care with ART through 96 weeks of follow up.
This study demonstrates that post-menopausal women benefit from ART and achieve responses
similar to those in pre-menopausal women which are maintained through 2 years of follow-
up. Therefore, clinicians should anticipate treatment naïve HIV-infected women should
achieve immunologic and virologic responses to ART regardless of menopause status.
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